Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.75
ESALY's Cash to Debt is ranked higher than
61% of the 1176 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. ESALY: 0.75 )
ESALY' s 10-Year Cash to Debt Range
Min: 0.3   Max: N/A
Current: 0.75

Equity to Asset 0.56
ESALY's Equity to Asset is ranked higher than
66% of the 978 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ESALY: 0.56 )
ESALY' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.56
Current: 0.56

0.37
0.56
Interest Coverage 12.82
ESALY's Interest Coverage is ranked higher than
56% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. ESALY: 12.82 )
ESALY' s 10-Year Interest Coverage Range
Min: 10.54   Max: 2966.46
Current: 12.82

10.54
2966.46
F-Score: 7
Z-Score: 2.81
M-Score: -3.32
WACC vs ROIC
4.07%
9.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.26
ESALY's Operating margin (%) is ranked higher than
76% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. ESALY: 10.26 )
ESALY' s 10-Year Operating margin (%) Range
Min: 2.42   Max: 16.84
Current: 10.26

2.42
16.84
Net-margin (%) 8.34
ESALY's Net-margin (%) is ranked higher than
77% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. ESALY: 8.34 )
ESALY' s 10-Year Net-margin (%) Range
Min: -2.32   Max: 10.55
Current: 8.34

-2.32
10.55
ROE (%) 9.13
ESALY's ROE (%) is ranked higher than
75% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. ESALY: 9.13 )
ESALY' s 10-Year ROE (%) Range
Min: -3.4   Max: 16.5
Current: 9.13

-3.4
16.5
ROA (%) 4.95
ESALY's ROA (%) is ranked higher than
75% of the 1187 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. ESALY: 4.95 )
ESALY' s 10-Year ROA (%) Range
Min: -1.78   Max: 9.24
Current: 4.95

-1.78
9.24
ROC (Joel Greenblatt) (%) 20.26
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1182 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. ESALY: 20.26 )
ESALY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.7   Max: 53.59
Current: 20.26

7.7
53.59
Revenue Growth (3Y)(%) -7.90
ESALY's Revenue Growth (3Y)(%) is ranked higher than
55% of the 974 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ESALY: -7.90 )
ESALY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 12
Current: -7.9

0
12
EBITDA Growth (3Y)(%) -11.40
ESALY's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ESALY: -11.40 )
ESALY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 45
Current: -11.4

0
45
EPS Growth (3Y)(%) -21.20
ESALY's EPS Growth (3Y)(%) is ranked higher than
59% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. ESALY: -21.20 )
ESALY' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.2   Max: 53.8
Current: -21.2

-21.2
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 46.90
ESALY's P/E(ttm) is ranked higher than
76% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.50 vs. ESALY: 46.90 )
ESALY' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 77.73
Current: 46.9

12.4
77.73
Forward P/E 18.32
ESALY's Forward P/E is ranked higher than
91% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 18.32 )
N/A
PE(NRI) 46.90
ESALY's PE(NRI) is ranked higher than
78% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.20 vs. ESALY: 46.90 )
ESALY' s 10-Year PE(NRI) Range
Min: 12.4   Max: 77.73
Current: 46.9

12.4
77.73
P/B 3.87
ESALY's P/B is ranked higher than
67% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. ESALY: 3.87 )
ESALY' s 10-Year P/B Range
Min: 1.76   Max: 4.27
Current: 3.87

1.76
4.27
P/S 3.89
ESALY's P/S is ranked higher than
65% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.31 vs. ESALY: 3.89 )
ESALY' s 10-Year P/S Range
Min: 0.96   Max: 6.6
Current: 3.89

0.96
6.6
PFCF 46.44
ESALY's PFCF is ranked higher than
82% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 662.20 vs. ESALY: 46.44 )
ESALY' s 10-Year PFCF Range
Min: 5.75   Max: 51.32
Current: 46.44

5.75
51.32
POCF 36.36
ESALY's POCF is ranked higher than
78% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.64 vs. ESALY: 36.36 )
ESALY' s 10-Year POCF Range
Min: 4.92   Max: 40.19
Current: 36.36

4.92
40.19
EV-to-EBIT 17.42
ESALY's EV-to-EBIT is ranked higher than
87% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.19 vs. ESALY: 17.42 )
ESALY' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 53.7
Current: 17.42

9.2
53.7
Shiller P/E 44.67
ESALY's Shiller P/E is ranked higher than
83% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 44.67 )
ESALY' s 10-Year Shiller P/E Range
Min: 15.89   Max: 49.37
Current: 44.67

15.89
49.37
Current Ratio 2.40
ESALY's Current Ratio is ranked higher than
72% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. ESALY: 2.40 )
ESALY' s 10-Year Current Ratio Range
Min: 1.85   Max: 2.81
Current: 2.4

1.85
2.81
Quick Ratio 1.97
ESALY's Quick Ratio is ranked higher than
75% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. ESALY: 1.97 )
ESALY' s 10-Year Quick Ratio Range
Min: 1.58   Max: 2.37
Current: 1.97

1.58
2.37
Days Inventory 176.59
ESALY's Days Inventory is ranked higher than
64% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. ESALY: 176.59 )
ESALY' s 10-Year Days Inventory Range
Min: 121.01   Max: 170.66
Current: 176.59

121.01
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.92
ESALY's Dividend Yield is ranked higher than
71% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. ESALY: 1.92 )
ESALY' s 10-Year Dividend Yield Range
Min: 1.58   Max: 5.42
Current: 1.92

1.58
5.42
Dividend Payout 1.00
ESALY's Dividend Payout is ranked higher than
72% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 1.00 )
ESALY' s 10-Year Dividend Payout Range
Min: 0.94   Max: 987.65
Current: 1

0.94
987.65
Yield on cost (5-Year) 2.00
ESALY's Yield on cost (5-Year) is ranked higher than
67% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. ESALY: 2.00 )
ESALY' s 10-Year Yield on cost (5-Year) Range
Min: 1.66   Max: 5.7
Current: 2

1.66
5.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 87.54
ESALY's Price/Net Current Asset Value is ranked higher than
74% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 87.54 )
ESALY' s 10-Year Price/Net Current Asset Value Range
Min: 17.43   Max: 244.85
Current: 87.54

17.43
244.85
Price/Tangible Book 7.65
ESALY's Price/Tangible Book is ranked higher than
59% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. ESALY: 7.65 )
ESALY' s 10-Year Price/Tangible Book Range
Min: 4.15   Max: 16.81
Current: 7.65

4.15
16.81
Price/DCF (Projected) 2.03
ESALY's Price/DCF (Projected) is ranked higher than
88% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 2.03 )
ESALY' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 1.19
Current: 2.03

0.72
1.19
Price/Median PS Value 2.47
ESALY's Price/Median PS Value is ranked higher than
54% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. ESALY: 2.47 )
ESALY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 3.61
Current: 2.47

0.64
3.61
Price/Graham Number 3.99
ESALY's Price/Graham Number is ranked higher than
75% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ESALY: 3.99 )
ESALY' s 10-Year Price/Graham Number Range
Min: 1.86   Max: 3.95
Current: 3.99

1.86
3.95
Earnings Yield (Greenblatt) 5.70
ESALY's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ESALY: 5.70 )
ESALY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 10.9
Current: 5.7

1.9
10.9
Forward Rate of Return (Yacktman) -6.45
ESALY's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.53 vs. ESALY: -6.45 )
ESALY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.7   Max: 18.4
Current: -6.45

-6.7
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:4523.Japan, EII.Germany,
Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Eisai to Promote Clinical Trial Data Disclosure for The Advancement of Science and Medicine May 21 2015
Eisai Launches In-house Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment... May 20 2015
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting May 14 2015
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog Apr 01 2015
Eisai Soars On Alzheimer's Drug With Biogen: How Much Is BIIB037 Worth? Mar 24 2015
Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog Mar 13 2015
Eisai Confirms Life-extending Breast Cancer Treatment Halaven® (Eribulin) to Remain on Cancer Drugs... Mar 10 2015
Merck Inks Deal with Eisai for Cancer Combo Therapy - Analyst Blog Mar 06 2015
Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 03 2015
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Feb 27 2015
Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog Feb 25 2015
Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog Feb 25 2015
Eisai Aghast at NHS England Decision to Remove Life Extending Breast Cancer Treatment From Cancer... Jan 12 2015
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Dec 19 2014
AstraZeneca/Eli Lilly Start Mid-Stage Alzheimer's Study Dec 02 2014
Epizyme Gains on Positive Phase I Data on EPZ-6438 Nov 21 2014
Eisai Neuroscience Business Officially Launched in Belgium and Luxembourg Nov 09 2014
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance Nov 05 2014
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK